M&A & Strategic Dealmaking: Illumina May Finally Be Ready to Unwind GRAIL Acquisition
After an eventful month in the Illumina-GRAIL saga, the story may soon be over.
After an eventful month in the Illumina-GRAIL saga, the story may soon be over.
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
The deal closed Feb.22, but the FTC has expressed concerns about the acquisition and Amazon’s business practices in general.